Further expanding its foot print in the generic drugs market, global drugs behemoth Pfizer is strengthening the collaboration announced earlier this year with Bangalore, India-based Strides Arcolab (The Pharma Letter January 7). It has now signed two licensing and supply agreements which address new markets and product segments.
Under the first agreement, Strides will license and supply up to 38 generic oncology products to Pfizer for markets in the European Union, Canada, Australia, New Zealand, Japan, and Korea. The second agreement covers niche sterile injectables for the US market. The finished dosage form products will be commercialized by Pfizer through its Established Products Business Unit. Financial terms of both agreements were not disclosed.
Pfizer aiming for market leadership in injectables
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze